Transmission of *Onchocerca volvulus* by *Simulium neavei* in Mount Elgon Focus of Eastern Uganda Has Been Interrupted

Moses Katarwa,* Tom Lakwo, Peace Habomugisha, Stella Agunyo, Edson Byamukama, David Oguttu, Richard Ndyomugenyi, Ephraim Tukesiga, Galex Orukan Ochieng, Francis Abwaimo, Ambrose Onapa, Dennis W. K. Lwamafa, Frank Walsh, Thomas R. Unnasch, and Frank O. Richards

The Carter Center, Atlanta, Georgia; Ministry of Health, Vector Control Division, Kampala, Uganda; The Carter Center Uganda, Kampala, Uganda; Ministry of Health, Kampala, Uganda; Kabarole District Health Services, Kabarole, Uganda; Mbale District Health Services, Mbale, Uganda; Strengthening Decentralization Systems (SDS), Mbale, Uganda; ENVISION/Research Triangle International, Vector Control Division, Ministry of Health, Kampala, Uganda; Lytham St. Anne's, Lancashire, United Kingdom; Global Health Infectious Disease Research, College of Public Health, University of South Florida, Tampa, Florida

Abstract. The study determined that *Simulium neavei*-transmitted onchocerciasis in Mount Elgon onchocerciasis focus had been interrupted. Annual mass treatment with ivermectin changed to two times per year along with vector elimination in 2007. Then, baseline microfilaria (mf) prevalence data of 1994 in five sentinel communities were compared with follow-up data in 2005 and 2011. Blood spots from 3,051 children obtained in 2009 were analyzed for *Onchocerca volvulus* immunoglobulin G4 antibodies. Fresh water crab host captures and blackflies collected indicated their infestation with larval stages of *S. neavei* and presence or absence of the vector, respectively. Mf rates dropped from 62.2% to 0.5%, and 1 (0.03%) of 3,051 children was positive for *O. volvulus* antibodies. Crab infestation dropped from 41.9% in 2007 to 0%, and *S. neavei* biting reduced to zero. Both remained zero for the next 3 years, confirming interruption of onchocerciasis transmission, and interventions were halted.

INTRODUCTION

At the 2002 conference on the eradicability of onchocerciasis, global eradicability of onchocerciasis was deemed impossible using currently available tools (ivermectin and vector control) because of the challenges posed by the infection in Africa.¹ However, permanent interruption of transmission in isolated transmission foci, where feasible in Africa, was recommended, with the goal of eventual elimination of the parasite and halting of interventions in those foci. The remaining meso- and hyper-endemic foci in Africa under the assistance of African Program for Onchocerciasis Control (APOC) were advised to continue annual mass drug administration (MDA) of ivermectin (Mectizan®; donated by Merck & Co., Whitehouse Station, NJ) with the goal of reaching a point of high-level control, where the disease resulting from the infection is no longer a public health problem.² However, the donation of ivermectin and questions of how long the mass ivermectin treatment programs would be needed in endemic areas have long been a concern to the public health community in endemic African countries, including Uganda.³

The immense health challenges of sustaining programs over time given frequent transfers of trained and committed personnel, shifting government policies, donor fatigue, and uncertain long-term political needed to justify long-term investment in the onchocerciasis control program prompted Uganda in 2007 to consider a move from control to an elimination approach.⁴ One determinant in this bold decision was the technical strength of Uganda's Vector Control Division, consisting of dedicated personnel trained by the German Gesellschaft für Technische Zusammenarbeit (GTZ), the Bernhard Nocht Institute for Tropical Medicine. Also, vector elimination efforts in the Itwara focus using focal ground larvicide application with Temephos (Abate) were successful.⁵ These findings, together with the Institutional Ministry of Health's knowledge of the

successful elimination of *Simulium damnosum* from the Victoria Nile focus that liberated 3 million people from the threat of onchocerciasis in 1970s, led to national confidence in declaring a countrywide elimination policy in 2007.⁶ In addition, there was, during this time period, evidence in the Americas that high-coverage semiannual MDA of ivermectin might actually kill the adult worms within 6.5 years.⁷ This time was a shorter time frame than necessary using annual treatments.⁸ The countrywide elimination policy for onchocerciasis used the strategy of a phased, integrated, and flexible program of aggressive mass treatment with ivermectin coupled with local vector elimination where ground larviciding was deemed technically feasible.

The Mount Elgon focus, the only onchocerciasis focus located in the eastern part of Uganda, was one of six Ugandan transmission foci initially targeted for the elimination effort. *S. neavei*, with larvae that occur in a phoretic association with the fresh water crabs *Potomonautes niloticus* and *P. loveni* in this area, are the vectors.⁹ Adult *S. neavei* require heavy forest canopy to survive and thrive.¹⁰

The first studies of the Mount Elgon focus were conducted in the 1950s, when it was observed that there was a small extension of the focus into Kenya.¹¹ On the Uganda side of the border, vector control activities against *S. neavei* were carried out in 1957, largely to protect a proposed coffee research station.¹² The estimated size of Mount Elgon focus in Uganda at the time was 1,500 km², with onchocerciasis mean prevalence of 80%. Vector control activities consisted of 12 applications of dichlorodiphenyltrichloroethane (DDT) (18% emulsifiable concentrate [e.c.]) at 0.5 ppm/30 minutes at 14-day intervals from 140 dosing points, which resulted in a 98% reduction of *S. neavei* density. However, vector elimination was not achieved.⁹ Because of the political upheavals, the plan to launch coffee research in the area was dropped, and additional onchocerciasis control activities were abandoned.¹³ However, on the Kenya side, vector control activities in 1950s and early 1960s were successful, and onchocerciasis was eliminated there.^{11,13,14} The size of the Mount Elgon focus in Uganda in the mid-1960s had reduced to about 500 km² as a result of deforestation.^{15,16} As widespread deforestation

*Address correspondence to Moses Katarwa, The Carter Center, One Copenhill, 453 Freedom Parkway, Atlanta, GA 30307. E-mail: mkataba@emory.edu

continued, the size of Mount Elgon focus was determined to be only 250 km² (unpublished survey by the Uganda National Onchocerciasis Control Program, 1994).

Onchocerciasis control was relaunched in Mount Elgon in 1994 and continued for 18 years. This paper reports treatment and assessment activities conducted in support of the conclusion that *onchocerca volvulus* transmission was interrupted in Mount Elgon, and interventions were halted at the end of 2011.

METHODS

History of recent assessments and treatment activities in the focus. By 1994, the Mount Elgon focus was comprised of parts of Mbale and Sironko districts; subsequently, two more districts (Bududa and Manafwa) were created from Mbale and Sironko districts (Figure 1). Rapid epidemiological assessment (REA) based on community nodule prevalence was done in 1994 in Mount Elgon to target ivermectin MDA.¹⁷ Samples of 30 resident adults ages 20 years and above who had lived in the community for at least 10 years were assessed for nodules.¹⁸ Annual mass treatment was launched in 1994 through community-based treatment. In 1998, communities were empowered to make their own decisions under the community-directed treatment with ivermectin (CDTI) approach.¹⁹

Under the new 2007 elimination policy, the CDTI strategy continued to be used, but the frequency of ivermectin distribution was changed from one to two times per year, and there was an increase in the geographic scope of treatments to include hypoendemic areas (communities with nodule rates below 20%) that had not been included in mass treatment.² Two times per year treatment was conducted for 5 years (2007–2011).

Treatment coverage was calculated by dividing treatments reported by the community-directed distributors (CDDs) by the total of all eligible persons (i.e., population minus children < 5 years who should not be treated with ivermectin) or the ultimate treatment goal (UTG) residing in all the at-risk communities within the onchocerciasis-endemic area. The entire

expanded focus (including hypoendemic communities) had a combined population of about 328,862 people in 820 communities. The denominator (UTG) used to calculate coverage in this report includes the hypoendemic communities.²⁰ Treatments in the Mount Elgon focus had been restricted to the priority meso- and hyperendemic areas from 1994 to 2006. As a result, the treatment coverage for the period for annual treatment could not reach the goal of 90% treatment coverage, because residents of hypoendemic areas were not included until 2007. With institution of two times per year treatment in 2007, the UTG under annual treatment doubled (hence, UTG2, which is number of treatments but not individual persons).²¹

National criteria for interruption of transmission. As part of the new elimination policy, the Ministry of Health (MOH) established the Uganda Onchocerciasis Elimination Expert Advisory Committee (UOEEAC) in 2008. As a first task, the UOEEAC recommended national criteria for making decisions on where and when to halt interventions.²² The guidelines developed were based on a detailed review of the 2001 World Health Organization (WHO) criteria for certification of elimination of onchocerciasis, tropical disease research (TDR) studies, and guidelines used by the Onchocerciasis Elimination Program for the Americas.^{23–25} The Uganda criteria include three indicators.

Parasitological assessments. Microfilaria (mf) prevalence in skin snips must be less than 5% in all sampled communities and less than 1% in 90% of sampled communities.²⁴

Serological assessments. Infection rates in children must be < 0.1%.²² The prevalence of immunoglobulin G4 (IgG4) antibodies to Ov-16, a recombinant antigen of *Onchocerca volvulus*, was used as a measure of infection/exposure in children.^{25–27} A sample size of 3,000 children is needed to exclude 0.1% antibody prevalence with 95% confidence.

Entomological assessments. In the *S. neavei* foci, there should be a lack of positive crabs for larvae/pupae of *S. neavei* species in a series of surveys and absence of *S. neavei* collected in a defined focus over a period of 3 year.⁵

FIGURE 1. Map of Mount Elgon onchocerciasis focus of eastern Uganda.

Parasitological assessments in 1994, 2005, and 2011. Baseline (pretreatment) mf rates were collected in four high-risk communities (determined based on high nodule rates from the wider 1994 nodule surveys described by Ndyomugenyi²⁸ in 1998). These results were compared with those results collected in the 2005 and 2011 follow-up surveys that used similar methods, with the exception that the 2011 survey added a fifth community. Another variant in the 2011 follow-up survey was that 87 children less than 10 years of age were examined from Buriri (8), Bubungi (27), Bunabutiti (22), Bunabatsu (15), and Bukikoso (15) communities. Two skin snips were taken from the iliac crest posteriorly for every selected adult.²⁹ Skin snips were read under low ($\times 40$) magnification after a 12-hour incubation at ambient temperature in normal saline solution. The mf in individual skin snips were not quantified but recorded as positive or negative, and the prevalence was expressed as a percentage.

Assessments in 2010. Serological assessments. Children were randomly selected from 17 communities from four districts comprising the Mount Elgon focus. Each district was proportionally assigned sampling numbers based on population sizes from census recording in the community household register of 2008. Also, proportional sampling was applied at low levels of administrative structures, such as the subcounty and parish levels below the district level. The proportion of children selected for assessment by district was 23.2% (812) from Sironko District, 19.7% (689) from Mbale District, 10.9% (381) from Manafwa District, and 46.2% (1,617) from Bududa District. Age group samples sought were also proportionally allocated: under 5 years = 1,500 (42.8%), ≥ 5 to ≤ 10 years = 1,000 (28.6%), and > 10 to < 14 years = 1,000 (28.6%).

Sterile procedures were used to collect blood spots on Whatman No. 2 filter paper (Sigma). The blood samples were dried, separated by sheets of paper, systematically bundled, and stored in plastic bags in a cooler until they were returned to the laboratory and stored at 4°C before being processed for analysis. Sera were eluted from the dried spots and examined for the presence of Ov-16 IgG4 antibodies by enzyme-linked immunosorbent assay (ELISA) as previously described.²⁵

Entomological activities. Mapping of vector breeding sites and their upper elevation breeding limits began in March of

2007. Fresh water crabs (*P. niloticus* and *P. loveni*) in all the rivers in this focus were trapped and examined for infestation with immature stages of *S. neavei* in 2007 to determine the magnitude of crab infestation.⁵ There are over 20 rivers and tributary streams in the focus, but only the three major systems that had infested crabs with the immature stages of *S. neavei* were targeted for vector elimination: the Namatala, the Namufumbulo, and the Tsutsu and their tributaries (Figure 2, river system). Sironko river system was found unsuitable for crabs and subsequently, the breeding of *S. neavei*, because the surrounding forest had been destroyed (Figure 1).^{5,30} Breeding of *S. neavei* was thought to be confined to the zone below 1,350 m, although adult *S. neavei* have been caught at altitudes as high as 2 100 m. Fresh water crabs were caught using locally designed funnel-shaped basket traps baited with fresh meat. They were left in rivers for at least 1 hour and then immediately examined for crabs carrying larvae and pupae of *S. neavei*.^{5,13} The crabs carrying young stages of *S. neavei* were counted, and infestation rate was expressed as a percentage of the total catch. Crabs were returned to the stream immediately after examination. Crab monitoring continued one time per month until October of 2011.

Adult *S. neavei* collection. Adult *S. neavei* collection following an MOH protocol based on WHO standards for full-day human landing catches of *S. neavei* (0700–1800 hours) were established at four catching sites: one on the Namufumbulo river system, two on the Namatala river system, and one on the Tsutsu river system (Figure 2).³¹ Female *S. neavei* seeking a blood meal settled on exposed legs of local collectors, who collected them in tubes before they bit. *S. neavei* collection was 2 days/week and 8 days/month until June of 2011, and the captures were preserved in ethanol. In a small study conducted in 2007, captured *S. neavei* were dissected to determine parous and infection rates before launching two times per year ivermectin treatments. Infection rate was defined as the proportion of *S. neavei* with all larval stages (L1, L2, and L3).^{18,32}

Larviciding. Larviciding with temephos was conducted and supervised by expert MOH vector control teams at all sites where infested crabs were observed.⁵ First insecticide carry trials were carried out at 27 dosing points from October to

FIGURE 2. Gauging and dosing points as well as fly-catching sites on river systems where *S. neavei* breeds in Mount Elgon focus.

FIGURE 3. History of mass treatment with ivermectin from 1994 to 2011 in Mount Elgon onchocerciasis focus in Uganda.

November of 2007. During this period, river gauging to establish the discharge and determine dosing and booster points was done. Temephos was applied at a rate of 0.2–0.4 mg/L to reach a concentration of 0.1–0.3 ppm. The insecticide was premixed in a 15-L knapsack sprayer and applied for a period of 30 minutes at established dosing points. Larviciding commenced in January of 2008 in all three river systems and continued for the next 12 months initially at 4-week intervals for 6 months and 8-week intervals thereafter until March of 2009. All 41 key dosing points plus an additional 6 booster points on these river systems were used in the first 6 months. Treatment at the booster points was discontinued when the program moved to 8-week treatments. The impact of the larviciding on *S. neavei* immature stages was assessed after 48 hours.^{5,30} When larviciding was stopped, surveillance through crab infestation and *S. neavei* collection continued through October of 2011 and June of 2011, respectively.

The MOH personnel also monitored crab populations in eight rivers where ground larviciding was not done in July of 2007, June of 2010, and June of 2011.

Data analysis. Parasitological data from adults and children and serological data from children were entered and analyzed in Microsoft Excel. Where relevant, the data were entered and analyzed in Epi Info (CDC, Atlanta, GA) for a χ^2 test of independence. The entomological data were also entered, analyzed, and graphically illustrated in Microsoft Excel.

Ethical approval of the study protocols. Parasitological, serological, and entomological evaluations were approved by the MOH of Uganda. The Emory Institutional Review Board (11 438) classified the assessment activities as periodical program performance assessment (non-research). In parasitological and serological epidemiology studies, consent was obtained from all participants, and verbal assent was obtained from the parents of young children. All participating communities were

FIGURE 4. History of percent treatment coverage with ivermectin annually from 1994 to 2005 (UTG) and two times per year (UTG2) from 2006 to 2011 in Mount Elgon onchocerciasis focus in Uganda.

TABLE 1

Trend of mf (microscopy) prevalence among adults (20 years and above) from 1994 baseline ($N = 320$) to follow-up surveys in the same communities in 2005 ($N = 528$) and 2011 ($N = 442$)

Community	Baseline (1993)			Follow-up (2005)			Follow-up (2011)		
	No. assessed	No. of persons positive for mf	Persons positive for mf (%)	No. assessed	No. of persons positive for mf	Persons positive for mf (%)	No. assessed	No. of persons positive for mf	Persons positive for mf (%)
Bubungi	80	60	75.0	154	3	1.9*	80	0	0*
Bunambutu	80	43	53.8	110	0	0.0*	100	0	0*
Bunabatsu	80	47	58.8	124	3	2.4*	118	1	0.9*
Buriri	80	49	61.3	140	2	1.4*	55	1	1.8*
Bukikoso	ND	ND	ND	ND	ND	ND	89	0	0
Overall	320	199	62.2	528	8	1.5*	442	2	0.5*

ND = not done.

*Significant ($P < 0.0001$) follow-up mf prevalence compared with the baseline.

educated about the importance of evaluations, and participants were assured that there would be no repercussions for refusing to participate. The *S. neavei* collectors were at least 20 years of age and provided written informed consent after they were informed of the nature of the work and told that they could opt out of the study if they so wished at any time without any repercussions.

RESULTS

Mass treatment. When mass treatments began in 1994, only 18,678 persons were treated. Treatments grew to 193,858 by 2006, the last year of annual treatment in hyper- and mesoendemic areas of Mount Elgon. When hypoendemic areas were added, treatments grew to over 270,000 treatments per round by 2011 (Figure 3). In terms of UTG coverage, the program reached no more than 73.5% in the period of 1994–2006. Beginning in 2007, when two times per year treatment was launched and hypoendemic areas were included, communities attained 90% of UTG in every treatment round every year from 2007 to 2011 (Figure 4).

Parasitological assessments. Among adults, baseline skin mf prevalence fell by more than 95% from 62.2% ($N = 320$) in 1994 to 1.5% ($N = 528$) in the 2005 follow-up assessments ($P < 0.0001$) and 0.5% ($N = 442$) in the 2011 follow-up assessments. However, the two adults who tested mf-positive during 2011 were more than 70 years old (Table 1). The prevalence of palpable nodules also decreased by more than 95% from 59.2% ($N = 120$) at baseline assessments in 1994 to 3.2% in the 2005 follow-up assessments ($P < 0.0001$) and 1.4% ($N = 442$) in the 2011 follow-up assessments (Table 2). All 87 children (≤ 10 years of age) assessed in 2011 were negative for both mf and palpable nodules, indicating no recent transmission in the communities.

Serological assessments in children with Ov-16 antibody ELISA.

In total, 3,051 blood spots were obtained, exceeding the sampling scheme goals for the younger age group (1,113, under 5 years; 1,032, ≥ 5 to ≤ 10 years) but not reaching the goal for the group of > 10 to < 15 years (906). Only one older child in the > 10 to < 14 years age group tested positive (0.03% with upper 95% confidence interval [95% CI] = 0.128%) (Table 3). By age groups, the results in children under 5 years were 0% (upper 95% CI = 0.172%), > 5 and ≤ 10 years were 0% (upper 95% CI = 0.185%), and > 10 and ≤ 14 years were 0.11% (upper 95% CI = 0.430%). In the 10 years and under cohort ($N = 2,145$), the rate was 0% (upper 95% CI = 0.089%).

Entomological assessments. *Monitoring of fresh water crabs.* The infestation level of about 41.9% (range = 47–59%) from April to December of 2007 declined to 27.7% (range = 15.6–34.6%) from January to April of 2008 with the commencement of larviciding. After April of 2008, the decline was dramatic, and the last infested crab was captured in August of 2008. Thereafter, no infested crab with larval stages of *S. neavei* was captured for the next 3 years (Figure 5). However, a progressive decline in the number of crabs captured to almost extinction during monitoring was noted, even after larviciding was halted in March of 2009. Monitoring of crab populations in eight river systems where no larviciding was done revealed a similar trend, with 698 crabs being captured in 2007; then, in June of 2010, only 43 crabs were captured, whereas in July of 2011, no crab was captured (Table 4).

S. neavei adult fly collection. *S. neavei* collections from April of 2007 show a year-round biting pattern, with a peak biting period between June and October. With the commencement of larviciding in January of 2008, a progressive decline in *S. neavei* collection was observed, and the last *S. neavei* were collected in June of 2008. The mean biting rate in 2007 of five *S. neavei* per man-hour had quickly been reduced to zero after

TABLE 2

Trend of nodule prevalence among adults (20 years and above) from 1994 baseline ($N = 120$) to follow-up surveys in the same communities in 2005 ($N = 528$) and 2011 ($N = 442$)

Community	Baseline (1993)			Follow-up (2005)			Follow-up (2011)		
	No. assessed	No. of persons positive for nodules	Positive for nodules (%)	No. assessed	No. of persons positive for nodules	Positive for nodules (%)	No. assessed	No. of persons positive for nodules	Positive for nodules (%)
Bubungi	30	22	73.3	154	6	3.9*	80	2	2.5*
Bunabutiti	30	18	60.0	110	3	2.7*	100	0	0.0*
Bunabatsu	30	12	40.0	124	3	2.4*	118	1	0.8*
Buriri	30	19	63.3	140	5	3.6*	55	0	0.0*
Bukikoso	ND	ND	ND	ND	ND	ND	89	3	3.4
Overall	120	71	59.2	528	17	3.2*	442	6	1.4*

ND = not done.

*Significant ($P < 0.0001$) follow-up nodule prevalence compared with the baseline.

FIGURE 6. Trend of *S. neavei* adult fly catches from April of 2007 to June of 2011.

that the Mount Elgon focus had met the Ugandan national criteria for transmission interruption and recommended to the MOH that interventions be halted. Subsequently, the MOH's National Certification Committee accepted the UOEEAC recommendation, and in 2012, ivermectin mass treatments in Mount Elgon were halted. If, during a 3-year post-treatment surveillance (PTS) phase, no evidence for renewed transmission is noted, the focus could be declared free of onchocerciasis.^{21–25}

The 2009 serological results from the Ov-16 antibody survey among children were discussed by the UOEEAC at length. The national criteria call for < 0.1% seroprevalence, and although the serosurvey found a prevalence of 0.03%, the upper bound of the 95% CI was just above 0.1% (at 0.128%). The UOEEAC concluded, however, that the one positive child was in an age group that likely represented an older transmission event, given the absence of infection in younger children. The UOEEAC unanimously recommended to stop interventions in Mount Elgon, despite the one positive child in the survey, while also urging any subsequent serosurveys to sample only children less than 10 years of age so as to avoid this problem in future.^{21,33} The national guidelines now require the seroprevalence of children under 10 years of age to be less than 0.1%.²¹

It was evident that deforestation rendered a large area unsuitable for *S. neavei* breeding and survival, resulting in progressive shrinking of the Mount Elgon focus from 1,500 km² in the 1950s to the current 250 km².^{15,16} In fact, tree felling and bush clearing was used in the 1940s and early 1950s successfully to control *S. neavei* in the Nyanza region of Kenya.³⁴ Deforestation is an important factor in reducing onchocerciasis in areas where the sole vector is *S. neavei*.³⁵ Deforestation was exacerbated by the population pressure on land (currently at about 1,315 persons/km²) in and around Mount Elgon. There was also evidence of declining crab host populations of *P. niloticus* and *P. loven*. Previous studies in western Uganda had implicated deforestation as a major factor driving the decline of the fresh water crab population.^{5,29} Our surveys conducted from 2007 to 2011 documented a dramatic decline in crab populations in both treated and untreated rivers, indicating that the decline that we observed was not related to the larviciding with temephos to control the vector population. On reflection, deforestation in the Mount Elgon focus may have also contributed to the interruption of transmission of onchocerciasis.

CONCLUSION

Transmission interruption in Mount Elgon validates the Ugandan MOH decision in 2007 to adopt an aggressive tactical approach to onchocerciasis elimination, including semiannual mass treatment of the afflicted communities with ivermectin and vector elimination/control efforts where feasible. Onchocerciasis elimination as a strategy should mean the reconfiguration of static onchocerciasis control programs to more flexible ones in an attempt to speed up the elimination process, and it should convey to all partners that elimination means that it can no longer be business as usual.

Received August 29, 2013. Accepted for publication February 24, 2014.

Published online March 31, 2014.

Acknowledgments: The authors acknowledge Mr. Hillary Kasibini, the first Onchocerciasis Control Co-ordinator for Mount Elgon focus (now retired). Also acknowledged are vector control officers in this focus, namely Fred Masaba, Primo Vunni, and Julius Kibumba, who supported vector elimination activities. We acknowledge Mr. Bernard Masaba from Sironko District, Miss Iren Nakke from Budada District, and Mr. Eira Emuron from Manafua District for their tireless effort to onchocerciasis elimination in Mount Elgon focus. We also acknowledge the medical officers of all the districts in Mount Elgon focus and other relevant district staff who participated in elimination activities. We thank the Uganda Wildlife Authority (UWA) staff, who provided protection to the team in the Mount Elgon National Park where the focus is situated. We acknowledge affected communities (their involvement enhanced interruption of *Onchocerca volvulus*) and the organizations that provided financial, technical, and material support, such as River Blindness Foundation (RBF), The Carter Center, Lions Clubs International Foundation, Lions Clubs of Uganda, and the African Program for Onchocerciasis Control (APOC). We acknowledge The Carter Center, Uganda staff Harriet Sengendo and Justine Ocaka as well as Zakia Washitu of the National Onchocerciasis Elimination Secretariat, Ministry of Health, Uganda. We acknowledge Dr. J. N. Raybould, who provided valuable insight into the evolution of the Mount Elgon focus in Kenya and Professor R. Garms for his insightful advice in vector elimination. We will ever be grateful to the late Nancy Cruz Ortiz, who provided technical support during the establishment of the molecular laboratory in Uganda that tested blood specimens reported in this paper. Mr. John Moores, who provided critical financial support for establishing this laboratory and launching of onchocerciasis elimination activities, is also acknowledged.

Authors' addresses: Moses Katabarwa, The Carter Center, Atlanta, GA, E-mail: mkataba@emory.edu. Tom Lakwo and David Oguttu, Vector Control Division, Ministry of Health, Kampala, Uganda, E-mails: tlakwo@gmail.com and dguttu@gmail.com. Peace Habomugisha, Stella Agunyo, and Edson Byamukama, Health Programs, The Carter Center,

Kampala, Uganda, E-mails: provia5@hotmail.com, agunyoeagunyuo@gmail.com, and edson.navs@gmail.com. Richard Ndyomugenyi, Ministry of Health, Kampala, Uganda, E-mail: richardndyomugenyi@gmail.com. Ephraim Tukesiga, Kabarole District Health Services, Fort Portal, Uganda, E-mail: ephraim.tukesiga@gmail.com. Galex Orukan Ochieng, Mbale District Health Services, Mbale, Uganda, E-mail: ochienggalex@yahoo.com. Francis Abwaimo, Health Services, Strengthening Decentralization Systems, Mbale, Uganda, E-mail: fabwaimo@gmail.com. Ambrose Onapa, RTI International, ENVISION, Kampala, Uganda, E-mail: kwibale1@yahoo.co.uk. Dennis W. K. Lwamafa, National Disease Control, Ministry of Health, Kampala, Uganda, E-mail: lwamafa@yahoo.co.uk. Frank Walsh, Entomology, Lythan St. Anne's, Lancashire, United Kingdom, E-mail: frank@walsh.me.uk. Thomas R. Unnasch, Global Health, University of South Florida, Tampa, FL, E-mail: tunnasch@health.usf.edu. Frank O. Richards, Health Programs, The Carter Center, Atlanta, GA, E-mail: frich01@emory.edu.

REFERENCES

- Dadzie Y, Neira M, Hopkins D, 2003. Final report of the Conference on the eradicability of Onchocerciasis. *Filaria J* 2: 2.
- Noma M, Nwoke BE, Nutall I, Tambala PA, Enyong P, Namsenmo A, Remme J, Amazigo UV, Kale OO, Sékétéli A, 2002. Rapid epidemiological mapping of onchocerciasis (REMO): its application by the African Programme for Onchocerciasis Control (APOC). *Ann Trop Med Parasitol* 96 (Suppl 1): S29–S39.
- Hopkins DR, Richards FO, Katabarwa M, 2005. Whither onchocerciasis control in Africa? *Am J Trop Med Hyg* 72: 1–2.
- Ndyomugenyi R, Lakwo T, Habomugisha P, Male B, 2007. Progress towards the elimination of onchocerciasis as a public-health problem in Uganda: opportunities, challenges and the way forward. *Ann Trop Med Parasitol* 101: 323–333.
- Garms R, Lakwo TL, Ndyomugenyi R, Kipp W, Rubaale T, Tukesiga E, Katamanywa J, Post RJ, Amazigo UV, 2009. The elimination of the vector *Simulium neavei* from the Itwara onchocerciasis focus in Uganda by ground larviciding. *Acta Trop* 111: 203–210.
- McCrae AW R, 1978. Intermittent eradication of *Simulium damnosum* Theo. on the Nile from Jinja, Uganda: 1951–1977. *Medical entomology centenary Symposium Proceedings* 23–25 November 1977: 133–134 London UK.
- Cupp EW, Cupp MS, 2005. Short report: impact of ivermectin community-level treatments on elimination of adult *Onchocerca volvulus* when individuals receive multiple treatments per year. *Am J Trop Med Hyg* 73: 1159–1161.
- Winnen M, Plaisier AP, Alley ES, Nagelkerke NJ, van Oortmarssen G, Boatin BA, Habbema JD, 2002. Can ivermectin mass treatments eliminate onchocerciasis in Africa? *Bull World Health Organ* 80: 384–391.
- Williams TR, 1991. Freshwater crabs and *Simulium neavei* in east Africa. III. Morphological variation in *Potamonautes loveni* (Decapoda: Potamidae). *Ann Trop Med Parasitol* 85: 181–188.
- Mpagi J, Katamanywa J, Garms R, 2000. Dispersal range of *Simulium neavei* in an onchocerciasis focus of western Uganda. *Med Vet Entomol* 14: 95–99.
- McMahon JP, Highton RB, Goiny H, 1958. The Eradication of *Simulium neavei* from Kenya. *Bull World Health Organ* 19: 75–107.
- Davies JB, 1994. Sixty years of onchocerciasis vector control: a chronological summary with comments on eradication, reinvasion, and insecticide resistance. *Annu Rev Entomol* 39: 23–45.
- Raybould JN, White GB, 1979. The distribution, bionomics and control of onchocerciasis vectors (Diptera: Simuliidae) in Eastern Africa and Yemen. *Tropenmed Parasitol* 30: 505–547.
- Roberts JM, Neumann E, Göckel CW, Highton RB, 1967. Onchocerciasis in Kenya 9, 11 and 18 years after elimination of the vector. *Bull World Health Organ* 37: 195–212.
- Colbourne MJ, Crosskey RW, 1965. *Onchocerciasis and Its Control in Uganda*. Geneva: World Health Organization.
- Prentice MA, 1974. *Simulium* control program in Uganda. *Research and Control of Onchocerciasis in the Western Hemisphere. PAHO Scientific Publications*. Washington, DC: Regional Office for the Americas of the World Health Organization, pp. 87–95.
- Katabarwa M, Onapa AW, Nakileza B, 1999. Rapid epidemiological mapping of onchocerciasis in areas of Uganda where *Simulium neavei* is the vector. *East Afr Med J* 76: 440–446.
- World Health Organization, 1991. *Strategies for Ivermectin Distribution Through Primary Health Care System*. Geneva: World Health Organization.
- Katabarwa MN, Habomugisha P, Agunyo S, McKelvey AC, Ogweng N, Kwebiha S, Byenume F, Male B, McFarland D, 2010. Traditional kinship system enhanced classic community-directed treatment with ivermectin (CDTI) for onchocerciasis control in Uganda. *Trans R Soc Trop Med Hyg* 104: 265–272.
- Richards FO Jr, Miri ES, Katabarwa M, Eyamba A, Sauerbrey M, Zea-Flores G, Korve K, Mathai W, Homeida MA, Mueller I, Hilyer E, Hopkins DR, 2001. The Carter Center's assistance to river blindness control programs: establishing treatment objectives and goals for monitoring ivermectin delivery systems on two continents. *Am J Trop Med Hyg* 65: 108–114.
- Katabarwa MN, Walsh F, Habomugisha P, Lakwo TL, Agunyo S, Oguttu DW, Unnasch TR, Unoba D, Byamukama E, Tukesiga E, Ndyomugenyi R, Richards FO, 2012. Transmission of onchocerciasis in Wadelai focus of northwestern Uganda has been interrupted and the disease eliminated. *Parasitol Res* 748540. doi:10.1155/2012/748540.
- Uganda Report, 2011. *Guidelines for Certification of Onchocerciasis Elimination in Uganda*. Kampala, Uganda: Uganda Government, Ministry of Health.
- World Health Organization, 2001. *Certification of Elimination of Human Onchocerciasis: Criteria and Procedures. Following a WHO Meeting on "Criteria for Certification of interruption of transmission/elimination of human onchocerciasis."* Geneva: World Health Organization.
- Diawara L, Traoré MO, Badji A, Bissan Y, Doumbia K, Goita SF, Konaté L, Mounkoro K, Sarr MD, Seck AF, Toé L, Tourée S, Remme JH, 2009. Feasibility of onchocerciasis elimination with ivermectin treatment in endemic foci in Africa: first evidence from studies in Mali and Senegal. *PLoS Negl Trop Dis* 3: e497.
- Lindblade KA, Arana B, Zea-Flores G, Rizzo N, Porter CH, Dominguez A, Cruz-Ortiz N, Unnasch TR, Punkosdy GA, Richards J, Sauerbrey M, Castro J, Catú E, Oliva O, Richards FO Jr, 2007. Elimination of *Onchocerca volvulus* transmission in the Santa Rosa focus of Guatemala. *Am J Trop Med Hyg* 77: 334–341.
- Lobos E, Weiss N, Karam M, Taylor HR, Ottesen EA, Nutman TB, 1991. An immunogenic *Onchocerca volvulus* antigen: a specific and early marker of infection. *Science* 251: 1603–1605.
- Lipner EM, Dembele N, Souleymane S, Alley WS, Prevots DR, Toe L, Boatin B, Weil GJ, Nutman TB, 2006. Field applicability of a rapid-format anti-Ov-16 antibody test for the assessment of onchocerciasis control measures in regions of endemicity. *J Infect Dis* 194: 216–221.
- Ndyomugenyi R, 1998. Onchocerciasis control in Uganda. *World Health Forum* 19: 192–195.
- Prost A, Prod'hon J, 1978. Le diagnostic parasitologique de l'onchocercose. Revue critique des méthodes en usage. *Médecine Tropicale: Revue du Corps de Santé Colonial* 38: 519–532.
- Fischer P, Garms R, Buttner DW, Kipp W, Bamuhiga J, Yocha J, 1997. Reduced prevalence of onchocerciasis in Uganda following either deforestation or vector control with DDT. *East Afr Med J* 74: 321–325.
- World Health Organization, 1995. *Onchocerciasis and Its Control. Report of a WHO Expert Committee on Onchocerciasis Control. Technical Report Series 852*. Geneva: World Health Organization.
- Davies JB, 1995. A rapid staining and clearing technique for detecting filarial larvae in alcohol-preserved vectors. *Trans R Soc Trop Med Hyg* 89: 280.
- PCC and OEPA, 2012. Guide to detecting a potential recrudescence of onchocerciasis during the post treatment surveillance period: the American paradigm. *Res Rep Trop Med* 3: 21–32.
- Buckley JJC, 1951. Studies on human onchocerciasis and *Simulium* in Nyanza Province, Kenya. II. The disappearance of *S. neavei* from a bush cleared focus. *J Helminthol* 25: 213–222.
- Walsh JF, Molyneuz DH, Birley MH, 1993. Deforestation: effects on vector-borne disease. *Parasitology* 106: s55–s75.